-
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.
For...
IN THE SPOTLIGHT
-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community... -
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Initial Treatment Options for HER2+ NSCLC Expand with New Zongertinib Approval
On February 26, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) as an initial treatment option for newly diagnosed... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both...
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
ケルン・バイオテックは、2026年ASCOにおいて、RET融合陽性非小細胞肺がん（NSCLC）に対するLunbotinib Fumarate（A400/EP0031）の重要な第II相臨床試験データを発表しました。
ケルン・バイオテックは、2026年ASCOにおいて、RET融合陽性非小細胞肺がん（NSCLC）に対するLunbotinib Fumarate（A400/EP0031）の重要な第II相臨床試験データを発表しました。
Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC
Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC
博十年，向愈行｜王立峰教授：CROWN 研究 7 年全文数据即将发布，刷新了晚期 NSCLC 靶向治疗的 PFS 纪录_腾讯新闻
Expert Panel Decision Framework: Progressive Strategies for Managing HER2-Mutated Advanced NSCLC
Expert Panel Decision Framework: Progressive Strategies for Managing HER2-Mutated Advanced NSCLC
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC